A USE OF GALANTAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE; TARGETING THE UNDERLYING CAUSE OF THE DISEASE - Patent 1272190

(19)

(11)

EP 1 272 190 A2

(12)

(88)	Date of publication A3:
	16.05.2002

(43)	Date of publication:
	08.01.2003 Bulletin 2003/02

(21)	Application number: 01919406.7

(22)	Date of filing: 28.03.2001

(51)	International Patent Classification (IPC)⁷: A61K 31/55, A61P 25/28

(86)	International application number:
	PCT/EP0103/551

(87)	International publication number:
	WO 0107/4364 (11.10.2001 Gazette 2001/41)

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
	Designated Extension States:
	AL LT LV MK RO SI

(30)

Priority:

03.04.2000 US 194262 P

(71)	Applicant: JANSSEN PHARMACEUTICA N.V.
	2340 Beerse (BE)

(72)	Inventors:
	PARYS, Wim, Louis, Julien Gaithersburg, MD 20882 (US) PONTECORVO, Michael Lawrenceville, NJ 08648 (US)

(74)	Representative: Quaghebeur, Luc
	Janssen Pharmaceutica N.V.,J&J Patent Law Department,Turnhoutseweg 30 2340 Beerse 2340 Beerse (BE)

(54)	A USE OF GALANTAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE; TARGETING THE UNDERLYING CAUSE OF THE DISEASE